Loading stock data…
PBH
$50.65-1.89 (-3.60%)
Pre-Market$50.79+0.14 (+0.28%)· Last close May 11
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Prestige Consumer Healthcare Inc. in the Healthcare sector is trading at $50.65. The stock is currently near its 52-week low of $49.28, remaining 19.5% below its 200-day moving average. Technical signals show oversold RSI of 25 and bearish MACD signal, explaining why PBH maintains its current current market pressure. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 25) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$50.65
Potential Upside
34.7%
Whystock Fair Value$68.21
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. The company operates...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.75B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
15.09
Beta
Defensive asset. Lower volatility than the S&P 500.
0.47
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
11.64%
Volume
Today's trading volume
712,661
Recent News
Exploring Analyst Estimates for Prestige Consumer Healthcare (PBH) Q4 Earnings, Beyond Revenue and EPS
Beyond analysts' top-and-bottom-line estimates for Prestige Consumer Healthcare (PBH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2026.
Rockwell Medical (RMTI) Reports Q1 Loss, Misses Revenue Estimates
Rockwell Medical (RMTI) delivered earnings and revenue surprises of -300.00% and -7.29%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
LeMaitre Vascular (LMAT) Tops Q1 Earnings Estimates
LeMaitre (LMAT) delivered earnings and revenue surprises of +2.52% and -0.15%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Has Prestige Consumer Healthcare (PBH) Fallen Too Far After Its 32% One-Year Share Price Drop
If you are wondering whether Prestige Consumer Healthcare's share price still reflects its underlying worth, it helps to start with how the market has been treating the stock recently. The share price last closed at US$55.13, with returns of a 5.8% decline over 7 days, a 17.9% decline over 30 days, a 9.9% decline year to date, a 32.3% decline over 1 year, a 13.1% decline over 3 years and a 24.4% gain over 5 years. Recent price weakness has come as investors reassess consumer health names...
Prestige Consumer Healthcare (PBH) Is Down 10.3% After Rising FTC Scrutiny and Bearish Signals - What's Changed
In early April 2026, Prestige Consumer Healthcare’s shares came under pressure as heightened regulatory concerns around healthcare consolidation and anticompetitive behavior unsettled investors and coincided with bearish technical trading signals. The combination of sector-wide regulatory anxiety and short-term technical weakness has introduced a new layer of uncertainty for Prestige, even as analysts’ broader view on the business remains more constructive. Against this backdrop of...